Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Prisca Nadine Casimiro"'
Autor:
Grâce Petula Urielle Fila-Fila, Felix Koukouikila-Koussounda, Fabien Roch Niama, Lauriate Prudencie Bissombolo Madingou, Jordy Exaucé Demboux, Aldi Fred Mandiangou, Stéphane Vembe Mahounga, Ahmed Jordy Doniama, Louis Régis Dossou-Yovo, Prisca Nadine Casimiro, Pembe Issamou Mayengue
Publikováno v:
Pathogens, Vol 13, Iss 8, p 709 (2024)
The control and management of malaria are linked to the quality of diagnosis. We sought to estimate the performance of routine microscopy for malaria diagnosis and assess the prevalence of submicroscopic Plasmodium (P.) falciparum infection among feb
Externí odkaz:
https://doaj.org/article/7924b0220f63494f8c8ba766b5711024
Autor:
Brice Pembet Singana, Prisca Nadine Casimiro, Brunelle Matondo Diassivi, Simon Charles Kobawila, Jean-Mermoz Youndouka, Leonardo K. Basco, Pascal Ringwald, Sébastien Briolant, Mathieu Ndounga
Publikováno v:
Malaria Journal, Vol 21, Iss 1, Pp 1-12 (2022)
Abstract Background In the Republic of the Congo, malaria represents a major public health problem affecting all age groups. A regular surveillance of the current efficacy of first-line anti-malarial drugs is required in the face of possible emergenc
Externí odkaz:
https://doaj.org/article/9e30d40be2974f038301245a8f52c864
Autor:
Brice Pembet Singana, Prisca Nadine Casimiro, Brunelle Matondo Diassivi, Simon Charles Kobawila, Jean-Mermoz Youndouka, Leonardo K. Basco, Pascal Ringwald, Sébastien Briolant, Mathieu Ndounga
Publikováno v:
Malaria Journal
Malaria Journal, 2022, 21 (1), pp.137. ⟨10.1186/s12936-022-04143-4⟩
Malaria Journal, 2022, 21 (1), pp.137. ⟨10.1186/s12936-022-04143-4⟩
Background In the Republic of the Congo, malaria represents a major public health problem affecting all age groups. A regular surveillance of the current efficacy of first-line anti-malarial drugs is required in the face of possible emergence and spr
Autor:
Richard Culleton, Richard Carter, Takafumi Tsuboi, Satoru Takeo, Anjali Yadava, Mathieu Ndounga, Cevayir Coban, Prisca Nadine Casimiro, Fadile Yildiz Zeyrek, Kazuyuki Tanabe
Publikováno v:
The Journal of Infectious Diseases. 200:1465-1469
Plasmodium vivax is not thought to be transmitted in western and central Africa, because of the very high prevalence of the red blood cell Duffy-negative phenotype in local populations, a condition which is thought to confer complete resistance again
Autor:
Rachida Tahar, David A. Malonga, Mathieu Ndounga, Francine Ntoumi, Prisca Nadine Casimiro, Leonardo K. Basco
Publikováno v:
Tropical Medicine & International Health. 12:1164-1171
The objective was to test the efficacy of sulfadoxine-pyremethamine (SP) monotherapy and establish the prevalence of mutations in dhfr and dhps in Brazzaville Congo. We recruited 97 patients aged 6-59 months with uncomplicated malaria who attended Te
Autor:
Godefroy Mallanda, Pembe Issamou Mayengue, Mathieu Ndounga, Freddy Nsonde-Ntandou, David A. Malonga, Rachida Tahar, Davy W. Matondo Maya, Prisca Nadine Casimiro, Valentine Miakassissa-Mpassi, Pascal Ringwald, Leonardo K. Basco, Francine Ntoumi
Publikováno v:
Acta Tropica. 103:163-171
Congo-Brazzaville has recently adopted artesunate-amodiaquine as the first-line antimalarial drug to replace chloroquine. Before the implementation of this new strategy, we conducted several clinical studies to assess the therapeutic efficacy of form
Autor:
Felix Koukouikila-Koussounda, Pembe Issamou Mayengue, Francine Ntoumi, Brunelle Diassivy Matondo, Prisca Nadine Casimiro, Mathieu Ndounga, Lee A ymar Ndounga Diakou, Leonardo K. Basco, Michel Bitemo
Publikováno v:
Malaria Journal
Malaria Journal, BioMed Central, 2015, ⟨10.1186/s12936-015-0918-6⟩
Malaria Journal, 2015, ⟨10.1186/s12936-015-0918-6⟩
Malaria Journal, BioMed Central, 2015, ⟨10.1186/s12936-015-0918-6⟩
Malaria Journal, 2015, ⟨10.1186/s12936-015-0918-6⟩
Background The Republic of Congo adopted a new anti-malarial treatment policy in 2006, with artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) as the first- and second-line anti-malarial drugs, respectively. Only three clinical studies ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1d2749e56eb267e2a6d1b0bfc1ecf6d
https://hal.archives-ouvertes.fr/hal-01284955
https://hal.archives-ouvertes.fr/hal-01284955
Autor:
Bruno Pradines, Brunelle Diassivy Matondo, Hervé Bogreau, Prisca Nadine Casimiro, Mathieu Ndounga, Louis Regis Dossou-Yovo, Rigobert Mbouka, Leonardo K. Basco, Kim Yen Ha Nguyen, Brice Pembet Singana
Publikováno v:
Malaria Journal
Malaria Journal, BioMed Central, 2016, 15, ⟨10.1186/s12936-015-1078-4⟩
Malaria Journal, 2016, 15, ⟨10.1186/s12936-015-1078-4⟩
Malaria Journal, BioMed Central, 2016, 15, ⟨10.1186/s12936-015-1078-4⟩
Malaria Journal, 2016, 15, ⟨10.1186/s12936-015-1078-4⟩
Background In the Republic of Congo, previous epidemiological studies have only been conducted in the south of the country where it is most accessible. Nationally representative data on the efficacy of new anti-malarial tools are lacking in the count
Autor:
Mathieu Ndounga, Philippe Brasseur, Dieudonné Loumouamou, Francine Ntoumi, Prisca Nadine Casimiro, Pembe Issamou Mayengue, Leonardo K. Basco
Publikováno v:
Malaria Journal, Vol 12, Iss 1, p 53 (2013)
Malaria Journal
Malaria Journal
Background Congo-Brazzaville adopted artemisinin-based combination therapy (ACT) in 2006. Artesunate-amodiaquine (AS + AQ) and artemether-lumefantrine are the first-line and second-line anti-malarial drugs to treat uncomplicated Plasmodium falciparum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::567e16197e6399672621d52b6c767436
http://www.documentation.ird.fr/hor/fdi:010058983
http://www.documentation.ird.fr/hor/fdi:010058983
Autor:
Rachida Tahar, Leonardo K. Basco, Mathieu Ndounga, Prisca Nadine Casimiro, Dieudonné Loumouamou
Publikováno v:
Malaria Research and Treatment, Vol 2012 (2012)
Malaria Research and Treatment
Malaria Research and Treatment
The Republic of the Congo adopted artemisinin-based combination therapies (ACTs) in 2006: artesunate-amodiaquine and artemether-lumefantrine as the first-line and second-line drugs, respectively. The baseline efficacy of artemether-lumefantrine was e